Skip to main content

Table 4 Subgroup analysis of the mOS of advanced NSCLC patients who received combination therapy with PD-1 inhibitors and antiangiogenic agents

From: Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study

Characters

mOS (months)

HR (95% CI)

p value

Gender

 Male vs. Female

24.4 vs. 13.4

0.563(0.302,1.048)

0.070

Age

 < 60 vs. > 60

15.9 vs. 22.6

1.354(0.775,2.364)

0.287

Stage

 IV vs. III

18.4 vs. 26.6

1.388(0.647,2.976)

0.399

Histology

 Adenocarcinoma vs. Squamous

16.1 vs. 26.0

1.550(0.874,2.749)

0.134

Smoke

 Yes vs. No

22.4 vs. 16.6

0.987(0.566,1.723)

0.964

Brain metastasis

 Yes vs. No

13.3 vs. 24.4

1.961(1.087,3.540)

0.025*

Liver metastasis

 Yes vs. No

13.4 vs. 24.4

2.260(1.194,4.276)

0.012*

Bone metastasis

 Yes vs. No

15.4 vs. 26.0

2.021(1.152,3.543)

0.014*

Pleural effusion

 Yes vs. No

15.0 vs. 22.4

1.816(0.893,3.692)

0.100

Treatment lines

 1line vs. 2 lines vs. ≥ 3 linesa

NA vs. 24.4 vs. 14.7

0.446(0.106, 1.877)

0.271

0.535(0.296, 0.969)

0.039*

PDL1 expression

 Negative vs. Positive

16.6 vs. 22.4

1.157(0.663,2.020)

0.608

 Negative vs. Low. vs. Higha

16.6 vs. 18.2 vs. 26.8

1.357 (0.614,3.001)

0.451

1.291 (0.543,3.071)

0.563

Gene mutation

 Wild vs. EGFR

22.6 vs. 12.7

0.485(0.249,0.945)

0.033*

 Wild vs. EGFR vs. KRASa

18.6 vs. 12.7 vs. 24.4

1.688(0.683, 4.172)

0.257

3.029(1.145,8.011)

0.026

  1. NSCLC Non-small cell lung cancer, mOS median overall survival, HR Hazard rate, CI Confidence interval, Squamous Squamous cell carcinoma, PD-L1 (programmed death ligand 1) expression, Negative, 0%; Positive, ≥ 1%; Low, 1%-49%; High, ≥ 50%. EGFR (epidermal growth factor receptor), including classical EGFR mutation and nonclassical EGFR mutation, KRAS Kirsten Rat Sarcoma Viral Oncogene Homologue
  2. *significance p values
  3. athe last group served as a control